肝静脉压力梯度对肝硬化临床终点事件的预测

何福亮; 欧晓娟; 王民; 张冠华; 王宇

doi:10.3969/j.issn.1001-5256.2020.09.004

肝静脉压力梯度对肝硬化临床终点事件的预测

DOI: 10.3969/j.issn.1001-5256.2020.09.004

首都医科大学附属北京友谊医院肝病中心

基金项目:

北京市医管局中心青苗人才课题(20180701)；首都临床特色应用研究与技术推广(Z171100001017037)；国家科技重大专项(2017ZX10105015002)；北京市医院管理局消化内科学科协同发展中心消化专项特色项目(XXT04)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1315
- HTML全文浏览量: 15
- PDF下载量: 140
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-05
- 出版日期: 2020-09-20

Value of hepatic venous pressure gradient in predicting clinical end events in liver cirrhosis

Liver Research Center,Beijing Friendship Hospital,Capital Medical University

Research funding:

摘要

摘要: 肝硬化是肝脏疾病的终末阶段,失代偿期肝硬化以门静脉高压为显著特征,目前肝静脉压力梯度是评估门静脉高压的"金标准",具有重要的临床意义。对肝静脉压力梯度在代偿期及失代偿期临床终点事件中的预测作用以及在门静脉高压药物治疗效果评价中的应用进行阐述,以期为临床早预测、早预防、早干预门静脉高压提供依据。
- 肝硬化 /
- 高血压,门静脉 /
- 肝静脉压力梯度
Abstract: Liver cirrhosis is the end stage of liver disease,and decompensated liver cirrhosis has the significant feature of portal hypertension. At present,hepatic venous pressure gradient( HVPG) remains the “gold standard”for evaluating portal hypertension and thus has great significance in clinical practice. This article elaborates on the value of HVPG in predicting end events in compensated and decompensated liver cirrhosis and the application of HVPG in evaluating the therapeutic effect of drugs in the treatment of portal hypertension,so as to provide a basis for early prediction,early prevention,and early intervention of portal hypertension in clinical practice.
- liver cirrhosis /
- hypertension,portal /
- hepatic vein pressure gradient

HTML全文

参考文献(42)

[1] ZHAO LH,JIA JD. Etiological diagnosis and standard treatment of portal hypertension should be taken seriously[J]. J Clin Hepatol,2019,23(1):10-12.(in Chinese)赵连晖，贾继东．应重视门静脉高压症的病因诊断及规范治疗[J]．临床肝胆病杂志，2019,23(1):10-12.

[2] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.

[3] GARCIA-TSAO G,ABRALDES JG,BERZIGOTTI A,et al.Portal hypertensive bleeding in cirrhosis:Risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the Study of Liver Diseases[J].Hepatology,2017,65(7):310-335.

[4] SONG T,RSSLE M,HE F,et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome:A systematic review and meta-analysis[J]. Dig Liver Dis,2018,50(4):323-330.

[5] VILLANUEVA C,ALBILLOS A,GENESCJ,et al．βblockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI):A randomised,double-blind,placebo-controlled,multicentre trial[J].Lancet,2019,393(10181):1597-1608.

[6] RIPOLL C,GROSZMANN R,GARCIA-TSAO G,et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology,2007,133(2):481-488.

[7] RAMANATHAN S,KHANDELWAL N,KALRA N,et al. Correlation of HVPG level with ctp score,MELD Score,ascites,size of varices,and etiology in cirrhotic patients[J]. Saudi J Gastroenterol,2016,22(2):109-115.

[8] TURCO L,VILLANUEVA C,LA MURA V,et al. Lowering portal pressure improves outcomes of patients with cirrhosis,with or without ascites:A Meta-analysis[J]. Clin Gastroenterol Hepatol,2020,18(2):313-327. e6.

[9] KARAGIANNAKIS DS,VOULGARIS T,SIAKAVELLAS SI,et al. Evaluation of portal hypertension in the cirrhotic patient:hepatic vein pressure gradient and beyond[J]. Scand J Gastroenterol,2018,53(10-11):1153-1164.

[10] MERKEL C,BOLOGNESI M,BELLON S,et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices[J]. Gastroenterology,1992,102(3):973-979.

[11] KIM TY,LEE JG,SOHN JH,et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J,2016,57(1):138-145.

[12] RIPOLL C,BAARES R,RINCN D,et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era[J]. Hepatology,2005,42(4):793-801.

[13] TREBICKA J,GU W,IBEZ-SAMANIEGO L,et al. Rebleeding and mortality risk are increased by ACLF but reduced by preemptive TIPS[J]. J Hepatol,2020.[Online ahead of print]

[14] CARDENAS A,ABRALDES JG. Classifying varices in cirrhosis:Who’s got the best look?[J]. Liver Int,2020,40(4):754-755.

[15] LIU C,LIU Y,SHAO R,et al. The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention[J]. Ann Transl Med,2020,8(4):91.

[16] XU G,LI F,MAO Y. Portal pressure monitoring-state-ofthe-art and future perspective[J]. Ann Transl Med,2019,7(20):583.

[17] LU Z,JIN B,ZHANG WH,et al. Clinical application of hepatic venous pressure gradient measurement after esophagogastric variceal bleeding in guiding secondary prevention for patients with liver cirrhosis[J]. J Clin Hepatol,2020,36(1):107-112.(in Chinese)路筝，金波，张文辉，等．肝硬化食管胃静脉曲张出血后肝静脉压力梯度测定指导二级预防的临床应用[J]．临床肝胆病杂志，2020,36(1):107-112.

[18] MOHKAM K,RODE A,DARNIS B,et al. Hepatic venous pressure gradient after portal vein embolization:An accurate predictor of future liver remnant hypertrophy[J]. Surgery,2018,164(2):227-232.

[19] VILLANUEVA C,GRAUPERA I,ARACIL C,et al. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis[J].Hepatology,2017,65(5):1693-1707.

[20] HERNNDEZ-GEA V,ARACIL C,COLOMO A,et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated withβ-blockers[J]. Am J Gastroenterol,2012,107(3):418-427.

[21] ALI A,BADAWY A,SONBOL A,et al. Study of the relationship between blood ammonia level and esophageal varices in patients with liver cirrhosis[J]. Afro-Egypt J Infect Endem Dis,2015,5(2):78-85

[22] JALAN R,de CHIARA F,BALASUBRAMANIYAN V,et al. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension[J]. J Hepatol,2016,64(4):823-833.

[23] SHARMA P,KUMAR A. Minimal hepatic encephalopathy in patients with cirrhosis by measuring liver stiffness and hepatic venous pressure gradient[J]. Saudi J Gastroenterol,2012,18(5):316-321.

[24] BERZIGOTTI A,REIG M,ABRALDES JG,et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis:A systematic review and Metaanalysis[J]. Hepatology,2015,61(2):526-536.

[25] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.

[26] RIPOLL C,GROSZMANN RJ,GARCIA-TSAO G,et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis[J].J Hepatol,2009,50(5):923-928.

[27] SUK KT,KIM EJ,KIM DJ,et al. Prognostic significance of hemodynamic and clinical stages in the prediction of hepatocellular carcinoma[J]. J Clin Gastroenterol,2017,51(3):285-293.

[28] KIM MY,BAIK SK,YEA CJ,et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis[J]. Eur J Gastroenterol Hepatol,2009,21(11):1241-1246.

[29] ZHANG DY,FRIEDMAN SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis[J]. Hepatology,2012,56(2):769-775.

[30] PINTER M,SIEGHART W,REIBERGER T,et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma———a pilot study[J]. Aliment Pharmacol Ther,2012,35(1):83-91.

[31] MATSUSHIMA H,FUJIKI M,SASAKI K,et al. Predictive value of hepatic venous pressure gradient for graft hemodynamics in living donor liver transplantation[J]. Liver Transpl,2019,25(7):1034-1042.

[32] KERBERT AJ,CHIANG FW,van der WERF M,et al. Hemodynamic response to primary prophylactic therapy with nonselectiveβ-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis:A meta-analysis[J]. Eur J Gastroenterol Hepatol,2017,29(4):380-387.

[33] VILLANUEVA C,ALBILLOS A,GENESCJ,et al. Development of hyperdynamic circulation and response toβ-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology,2016,63(1):197-206.

[34] RODRIGUES SG,MENDOZA YP,BOSCH J. Beta-blockers in cirrhosis:Evidence-based indications and limitations[J].JHEP Rep,2020,2(1):100063.

[35] MERKEL C,BOLOGNESI M,SACERDOTI D,et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis[J]. Hepatology,2000,32(5):930-934.

[36] LEE SH,PARK SH,KIM GW,et al. Comparison of the Model for End-stage Liver Disease and hepatic venous pressure gradient for predicting survival in patients with decompensated liver cirrhosis[J]. Korean J Hepatol,2009,15(3):350-356.

[37] PARK SH,PARK HY,KANG JW,et al. Identification of patients with decompensated cirrhosis at high risk for death:Improving the prediction by hepatic venous pressure gradient?[J]. Hepatogastroenterology,2012,59(120):2548-2551.

[38] RIPOLL C,LASTRA P,RINCN D,et al. Comparison of MELD,HVPG,and their changes to predict clinically relevant endpoints in cirrhosis[J]. Scand J Gastroenterol,2012,47(2):204-211.

[39] Chinese Portal Hypertension Diagnosis and Monitoring Study Group(CHESS); Minimally Invasive Intervention Collaborative Group,Chinese Society of Gastroenterology; Emergency Intervention Committee,Chinese College of Interventionalists,et al. Consensus on clinical application of hepatic venous pressure gradient in China(2018)[J]. J Clin Hepatol,2018,34(12):2526-2536.(in Chinese)中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会，等．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．临床肝胆病杂志，2018,34(12):2526-2536.

[40] QI X,AN W,LIU F,et al. Virtual hepatic venous pressure gradient with ct angiography(CHESS 1601):A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology,2019,290(2):370-377.

[41] LIU F,NING Z,LIU Y,et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis(CHESS1701):A prospective multicenter study[J]. EBio Medicine,2018,36:151-158.

[42] LIU Y,NING Z，RMECI N,et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2020.[Online ahead of print]

施引文献

资源附件(0)

访问统计